Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $96.04 million versus the consensus estimate of $92.24 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Brookfield offers A$4.75/sh for Reliance Worldwide - Bloomberg
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance